Please login to the form below

Not currently logged in
Email:
Password:

US and Canada

This page shows the latest US and Canada news and features for those working in and with pharma, biotech and healthcare.

Merck, Eisai’s Keytruda/Lenvima regimen scores full approval in endometrial cancer

Merck, Eisai’s Keytruda/Lenvima regimen scores full approval in endometrial cancer

Merck &Co – known as MSD outside the US and Canada – and Eisai have announced that their immunotherapy combination Keytruda plus Lenvima has been approved in the US to treat endometrial cancer. . ... The US Food and Drug Administration (FDA) has

Latest news

More from news
Approximately 0 fully matching, plus 276 partially matching documents found.

Latest Intelligence

  • Surviving cancer: a new era for patients Surviving cancer: a new era for patients

    it was reported that five-year cancer survival rates are increasing globally, with the US, Canada and Australia among the highest. ... a terminal disease, and more towards helping cancer patients manage their condition effectively.

  • Health trust in a COVID-19 world – a unique opportunity for pharma Health trust in a COVID-19 world – a unique opportunity for pharma

    There are notable increases in ten of the 11 markets included in the Trust Barometer Spring Update, with the largest gains in trust seen in Canada, Germany and the US. ... This sub-sector had the highest increase in trust globally and, mirroring the

  • GSK forges ahead with its dynamic COPD and asthma portfolio GSK forges ahead with its dynamic COPD and asthma portfolio

    doing very well and you can also identify patients with ongoing, unmet need. ... For instance, in the UK, US, Canada and Spain, the first treatment was an ICS/LABA, such Seretide or Symbicort, while in Germany it was a bronchodilator.

  • Deal Watch October 2018

    US. US and Canada only. # US and EU. Roche’s collaboration with Ionis Pharmaceuticals has a headline of $760m, $1m more than the Tusk deal. ... milestones and royalties, and US profits or losses will be split 50:50.

  • Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

    She is Alnylam’s senior vice president, Europe and Canada and is based at the firm’s European headquarters in Zug, Switzerland. ... In the US and Canada, the company has launched Alynlam Act, a free of charge genetic testing and counselling service.

More from intelligence
Approximately 0 fully matching, plus 39 partially matching documents found.

Latest appointments

  • EFPIA appoints Hubertus von Baumbach as president EFPIA appoints Hubertus von Baumbach as president

    Baumbach had been a member of Boehringer’s board of managing directors since 2009, and he has also previously worked at Roche in the US and for Boehringer in Canada. ... that the EU remains an innovation leader and to build a healthier future for

  • Merck & Co appoints Frank Clyburn as president, human health Merck & Co appoints Frank Clyburn as president, human health

    Merck &Co – known as MSD outside the US and Canada – has appointed Frank Clyburn (pictured above) as president, human health. ... Clyburn joined Merck &Co in 2008 and during his time with the company, he has had responsibility for various global

  • McCann Health North America appoints Jim Joseph as president McCann Health North America appoints Jim Joseph as president

    Joseph will oversee all North American advertising and promotion agencies in the US and Canada. ... In his new role at McCann Health, he will oversee all North American advertising and promotion agencies in the US and Canada, and will build and expand

  • NDA bolsters its senior team NDA bolsters its senior team

    US, Europe, Canada and other markets. ... Her contributions will help propel client strategy and accelerate programmes across the EU and US, as well as result in new intriguing service offerings that enable innovative companies to navigate the

  • Celgene’s president and COO to retire Celgene’s president and COO to retire

    Smith has over 30 years of business strategy experience across a range of therapeutic areas, having previously held senior leadership roles at Biovail in Canada, France, the US and Hong Kong, ... Smith's successor, Curran, joined Celgene in 2013 as the

More from appointments
Approximately 0 fully matching, plus 19 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 9 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Spirit

We find the soul in the science, the humanity in the data, harnessing the power of creativity to deliver medical...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....